共 27 条
- [22] Rationale and design for a multicenter, randomized, double-blind, placebo- controlled, phase 2 study evaluating the safety and efficacy of the soluble guanylate cyclase stimulator praliciguat over 12 weeks in patients with heart failure with preserved ejection fraction (CAPACITY HFpEF) AMERICAN HEART JOURNAL, 2020, 222 : 183 - 190
- [24] Comparative Effect of Two Types of Physical Exercise for the Improvement of Exercise Capacity, Diastolic Function, Endothelial Function and Arterial Stiffness in Participants with Heart Failure with Preserved Ejection Fraction (ExIC-FEp Study): Protocol for a Randomized Controlled Trial JOURNAL OF CLINICAL MEDICINE, 2023, 12 (10)
- [25] Letter to the editor: "Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials involving 2624 patients" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (11) : 1841 - 1842
- [26] Author's reply to the letter to the editor: "Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients" EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2024, 80 (11) : 1843 - 1844
- [27] Effect of sacubitril/valsartan on sinus rhythm maintenance after catheter ablation in patients with persistent atrial fibrillation without reduced ejection fraction heart failure: a study protocol for a multi-center, open-label, randomized, controlled, superiority clinical trial FRONTIERS IN CARDIOVASCULAR MEDICINE, 2024, 11